Preclinical modeling of chronic inhibition of the Parkinson’s disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo

Preclinical modeling of chronic inhibition of the Parkinson’s disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo

Abstract The most common mutation in the Leucine-rich repeat kinase 2 gene (LRRK2), G2019S, causes familial Parkinson’s Disease (PD) and renders the encoded protein kinase hyperactive. While targeting LRRK2 activity is currently being tested in clinical trials as a therapeutic avenue for PD, to date...

Full description

Bibliographic Details
Main Authors: Jillian H. Kluss, Melissa Conti Mazza, Yan Li, Claudia Manzoni, Patrick A. Lewis, Mark R. Cookson, Adamantios Mamais
Format: Article
Language:English
Published: BMC 2021-03-01
Series:Molecular Neurodegeneration
Online Access:https://doi.org/10.1186/s13024-021-00441-8

Internet

https://doi.org/10.1186/s13024-021-00441-8

Similar Items